ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
38 announcements
Rubicon Research reported audited FY26 results and recommended a ₹1.50 per share dividend. The performance reflects steady growth and continued shareholder returns.
Rubicon Research scheduled a board meeting for May 29, 2026, to approve annual audited financial results. Directors will also consider a dividend recommendation for the fiscal year.
Rubicon Research Limited completed the acquisition of an 85% stake in Arinna Lifesciences Limited on April 30, 2026. Following this transaction, Arinna Lifesciences has become a subsidiary of the company. This move follows the terms of a previously signed Share Purchase Agreement.
Rubicon Research Limited announced the successful conclusion of an unannounced USFDA inspection at its R&D facility in Concord, Ontario, Canada. The inspection, conducted from April 20 to April 24, 2026, concluded without any Form-483 observations being issued. This outcome confirms the company's adherence to high quality and compliance standards.
Rubicon Research Limited received an Income Tax Assessment Order for AY 2023-24 with a demand of ₹17.25 Crore. The demand relates to Arms' Length Pricing adjustments. The company is in the process of filing an appeal and remains confident in its legal position.
Rubicon Research Limited is acquiring an 85% stake in Arinna Lifesciences Limited for approximately ₹175.92 Crore. This acquisition facilitates Rubicon's entry into the Indian CNS formulations market. The transaction values Arinna at an enterprise value of ₹200 Crore and is expected to close within 30 days.
Rubicon Research Limited is acquiring an 85% stake in Arinna Lifesciences Limited for approximately ₹175.92 Crore. Arinna is a specialist in the CNS therapeutic segment with a dedicated field force. This acquisition allows Rubicon to leverage its IP and chronic products portfolio while gaining access to Arinna’s established Indian sales and distribution network.
Rubicon Research Limited entered into definitive agreements to acquire an 85% stake in Arinna Lifesciences Limited for approximately ₹175.92 Crore. Arinna, a CNS-focused pharmaceutical marketing company with ₹71.5 Crore FY25 turnover, will become a subsidiary. The acquisition strengthens Rubicon's Indian market presence and distribution network for specialty products.